360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

PSIVIDA CORP

Type: Company

Name: PSIVIDA CORP (pSivida Limited)

Fact Sheet: Fact Sheet for pSivida Limited

First reported 13 hours ago - Updated 13 hours ago - 1 reports

pSivida announces availability of diabetic macular edema drug in Germany

pSivida Corp., a developer of drug delivery products for treatment of back-of-the-eye diseases, has announced the commercial availability of ILUVIEN, a sustained release pharmaceutical product for the treatment of chronic diabetic macular edema in Germany. ... [Published Individual.com - 13 hours ago]

Entities: PSIVIDA CORP, Iluvien, Diabetic Macular Edema

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Australian Securities Exchange

pSivida Corp Reports Third Quarter Fiscal Year 2013 Results

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced ... [Published BioSpace - May 14 2013]

Entities: PSIVIDA CORP, Fiscal Year, Australian Securities Exchange

First reported May 13 2013 - Updated May 14 2013 - 1 reports

pSivida (PSDV): FQ3 EPS of -$0.12 beats by $0.01. Revenue of $513K misses by $137K. Shares +3.8% AH. (PR)

:13 PM ET pSivida (PSDV): FQ3 EPS of -$0.12 beats by $0.01. Revenue of $513K misses by $137K. Shares +3.8% AH. (PR) ... [Published Seeking Alpha - May 13 2013]

Entities: PSIVIDA CORP, Stocks

First reported May 14 2013 - Updated May 14 2013 - 2 reports

pSivida: New ILUVIEN PDUFA Date October 17 [Professional Services Close - Up]

pSivida Corp., a developer of sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced that the U.S. Food and Drug Administration (FDA) acknowledged receipt of the resubmission of the New Drug Application (NDA) for ... [Published Pharmacy Choice - May 14 2013]

Entities: Iluvien, Diabetic Macular Edema, PSIVIDA CORP, Prescription Drug User Fee Act

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Apple Inc

pSivida Corp's CEO Discusses Q3 2013 Results - Earnings Call Transcript

DRI GOOG efii ETFPY eeb EAT dia AXP AAPL DELL SPY dsdfs nflx DIS ETFC et ETF DKK dgp DVR ... [Published Zecco - May 14 2013]

Entities: PSIVIDA CORP, Apple Inc, Google Inc

First reported May 13 2013 - Updated May 13 2013 - 2 reports

Antisense Therapeutics Ltd

Just Published: Global Diabetic Retinopathy Market 2012-2016 - MarketResearchReports.Biz

TechNavio's analysts forecast the Global Diabetic Retinopathy Market to grow at a CAGR of 35.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the Increase in Diabetic Population Worldwide. The Global Diabetic ... [Published MyNewsDesk - May 13 2013]

Entities: Market, Novagali Pharma SA, Excaliard Pharmaceuticals Inc, Antisense Therapeutics Ltd

First reported May 09 2013 - Updated May 09 2013 - 1 reports

pSivida launches chronic DME treatment in Germany

pSivida's ILUVIEN, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), is now commercially available in Germany.pSivida's ILUVIEN, the first sustained release pharmaceutical product for the treatment ... [Published Pro Health Service Zone - May 09 2013]

Entities: Diabetic Macular Edema, PSIVIDA CORP, Iluvien

First reported May 08 2013 - Updated May 08 2013 - 3 reports

pSivida Corp reports treatment of first patient with ILUVIEN in Germany following its market launch

Drug delivery products company pSivida Corp (NASDAQ:PSDV) announced on Tuesday the commercial launch of ILUVIEN, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), in Germany.In conjunction with ... [Published Individual.com - May 08 2013]

Entities: Iluvien, PSIVIDA CORP, Germany, Diabetic Macular Edema

First reported May 08 2013 - Updated May 08 2013 - 2 reports

Anthera Announces Additional Data from Phase 2b PEARL-SC; pS. . .

Anthera Announces Additional Data from Phase 2b PEARL-SC; pSivida Announces Commercial Launch of ILUVIENStaff and Wire ReportsBioMed ReportsBelow is a look at some of the headlines for companies that made news in the healthcare sector on May 7, 2013.Anthera ... [Published Equities.com - May 08 2013]

Entities: Systemic Lupus Erythematosus, Iluvien, Anthera Pharmaceuticals Inc, Phase IIb

First reported May 02 2013 - Updated May 02 2013 - 2 reports

Alimera Sciences introduces Iluvien in UK market

pSivida Corp., a specialty pharmaceutical company, has announced that its licensee, Alimera Sciences has introduced Iluvien, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), in the UK for treatment ... [Published PharmaBiz - May 02 2013]

Entities: Iluvien, Alimera Sciences Inc, Diabetic Macular Edema, PSIVIDA CORP

First reported Apr 30 2013 - Updated May 01 2013 - 3 reports

pSivida (PSDV) Receives New PDUFA Date for ILUVIEN

pSivida Corp. (Nasdaq: PSDV) announced that the U.S. Food and Drug Administration (FDA) acknowledged receipt of the resubmission of the New Drug Application (NDA) for ILUVIEN for treatment of chronic diabetic macular edema (DME) and stated that the resubmission ... [Published Street Insider - May 01 2013]

Entities: Iluvien, Diabetic Macular Edema, Prescription Drug User Fee Act, PSIVIDA CORP

First reported Apr 29 2013 - Updated Apr 29 2013 - 3 reports

pSivida launches DME treatment for the privately-insured in UK

Paul Ashton, CEO of pSivida, said it's pleased that Iluvien is now available in the UK for patients who suffer from DME and who have not responded to conventional therapies.The partner of Watertown, Mass.-based pSivida Corp. (Nasdaq:PSDV) has made a treatment ... [Published Boston Business Journal - Apr 29 2013]

Entities: PSIVIDA CORP, Diabetic Macular Edema, Iluvien, United Kingdom

Quotes

Ashton added, "We are also very pleased by Alimera's resubmission of the NDA for ILUVIEN to the FDA and the recently announced PDUFA goal date of October 17, 2013. We will be entitled to 20% of net profits, as defined, in each of Germany and the UK from sales of ILUVIEN by Alimera. If the FDA approves ILUVIEN, we would also be entitled to an additional $25 million milestone payment from Alimera as well as 20% of net profits on any sales in the US by Alimera."

pSivida announces availability of diabetic macular edema drug in Germany [Published Individual.com - 13 hours ago]

...Paul Ashton, President and CEO of pSivida Corp. "If the FDA approves ILUVIEN, we would be entitled to an additional $25 million milestone payment from Alimera as well as 20 percent of net profits, as defined, on any sales in the U S by Alimera. We are entitled to the same net profit share on sales of ILUVIEN for DME by Alimera in the EU, where Alimera has already launched in the UK and reported plans to launch in Germany in 2013."

pSivida: New ILUVIEN PDUFA Date October 17 [Professional Services Close - Up] [Published Pharmacy Choice - May 14 2013]

...with the implant injection since the product became commercially available," said Dan Myers, Alimera's president and chief executive officer. "This is a significant milestone for not only our Company but also for the patients suffering from the debilitating effects of chronic diabetic macular edema in these regions and their physicians." On April 29, 2013, Alimera announced that ILUVIEN had become commercially available in the United Kingdom...

Alimera Sciences Reports First Quarter 2013 Financial Results PR Newswire [Published Yahoo! Finance - May 09 2013]

...as to Alimera's ability to commercialize, and market acceptance of, ILUVIEN in the EU, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2012, which is on file with the Securities and Exchange Commission (SEC)...

Alimera Sciences Reports First Quarter 2013 Financial Results [Published Individual.com - May 09 2013]

More Content

sort by: Date \| Relevance
pSivida announces availability of diabetic macu... [Published Individual.com - 13 hours ago]
pSivida Corp Reports Third Quarter Fiscal Year ... [Published BioSpace - May 14 2013]
pSivida: New ILUVIEN PDUFA Date October 17 [Pro... [Published Pharmacy Choice - May 14 2013]
pSivida Corp's CEO Discusses Q3 2013 Results - ... [Published Seeking Alpha - May 14 2013]
pSivida Corp's CEO Discusses Q3 2013 Results - ... [Published Zecco - May 14 2013]
pSivida (PSDV): FQ3 EPS of -$0.12 beats by $0.0... [Published Seeking Alpha - May 13 2013]
pSivida Corp. Reports Third Quarter Fiscal Year... [Published EON Business - May 13 2013]
pSivida Corp. Reports Third Quarter Fiscal Year... [Published EON Science - May 13 2013]
pSivida Corp. Reports Third Quarter Fiscal Year... [Published Business Wire Health News - May 13 2013]
Just Published: Global Diabetic Retinopathy Mar... [Published MyNewsDesk - May 13 2013]
Global Diabetic Retinopathy Market 2012-2016 \| ... [Published MyNewsDesk - May 13 2013]
Alimera Sciences Reports First Quarter 2013 Fin... [Published Yahoo! Finance - May 09 2013]
Alimera Sciences Reports First Quarter 2013 Fin... [Published Individual.com - May 09 2013]
pSivida launches chronic DME treatment in Germany [Published Pro Health Service Zone - May 09 2013]
pSivida Corp reports treatment of first patient... [Published Individual.com - May 08 2013]
US EQUITIES OPENING HEADLINES INCLUDING: ExxonM... [Published Proactiveinvestors United Kingdom RSS feed - May 08 2013]
pSivida Iluvien available in Germany [Published PBR - News - May 08 2013]
BIOL Does A Deal, BLRX's Lined Up Events, CBST ... [Published RTTNews.com - May 08 2013]
pSivida Corporation achieves commercial launch ... [Published Proactive Investors Australia - May 08 2013]
Anthera Announces Additional Data from Phase 2b... [Published Equities.com - May 08 2013]
Anthera Announces Additional Data from Phase 2b... [Published BioMedReports - May 08 2013]
pSivida Corp. Announces Commercial Launch of IL... [Published EON Business - May 07 2013]
pSivida Corp. Announces Commercial Launch of IL... [Published Business Wire Health News - May 07 2013]
pSivida Corp. Announces Third Quarter 2013 Fina... [Published EON Business - May 06 2013]
pSivida Corp. Announces Third Quarter 2013 Fina... [Published Business Wire Health News - May 06 2013]
Ophthalmology: A Niche Where Innovation Pays [Published Seeking Alpha - May 06 2013]
pSivida: New ILUVIEN PDUFA Date October 17 [Published Individual.com - May 06 2013]
Alimera Sciences introduces Iluvien in UK market [Published PharmaBiz - May 02 2013]
AGEN's Brain Cancer Vaccine Works, AVEO On Watc... [Published RTTNews.com - May 02 2013]
Shire's Vyvanse Approved in US; Raptor's PROCYS... [Published BioMedReports - May 02 2013]

Blogs

sort by: Date \| Relevance
pSivida Iluvien available in Germany [Published PBR - News - May 08 2013] pSivida has announced the availability of the sustained release pharmaceutical product indicated for the treatment of chronic diabetic macular edema (DME), Iluvien, in Germany. ...
IBM is a Buy and 3 More Analyst Upgrades to Kno... [Published Wall St. Cheat Sheet - Apr 10 2013] Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up ...
Acuvax to gain breast and stomach cancer vaccin... [Published Proactiveinvestors United Kingdom website - Apr 08 2013] Acuvax ( ASX:ACU ) is in the process of acquiring Biolife Science Qld Ltd, backed by Dr Roger Aston and Paul Hopper, via a reverse takeover and looking to raise $5 million from investors via a prospectus issue in a corporate vehicle Acuvax Limited.Acuvax ...
Pharmacy News [Published Rx Times Pharmacy Magazine - Nov 30 2012] pSivida Corp. Reports Patient Access Scheme Being Developed by Alimera to Address Cost Concerns Following Negative Final Draft Guidance by U.K.’s NICE for ILUVIEN® for DME WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida reports patient access scheme being developed ...

Press Releases

sort by: Date \| Relevance
pSivida Corp. Reports Third Quarter Fiscal Year... [Published EON Business - May 13 2013]
pSivida Corp. Reports Third Quarter Fiscal Year... [Published EON Science - May 13 2013]
pSivida Corp. Reports Third Quarter Fiscal Year... [Published Business Wire Health News - May 13 2013]
pSivida Corp. Announces Commercial Launch of IL... [Published EON Business - May 07 2013]
pSivida Corp. Announces Commercial Launch of IL... [Published Business Wire Health News - May 07 2013]